Founded in 2022, Irazú Oncology is pioneering a new generation of cancer immunotherapies through our proprietary OMV (outer membrane vesicle) technology. Building upon over 15 years of groundbreaking research at the University of Maryland’s Center for Vaccine Development and Global Health, we’re dedicated to breaking barriers in cancer care.
Irazú Oncology addresses the limitations of traditional cancer treatments through our revolutionary OMV platform, which delivers breakthrough immunotherapies at significantly lower costs than personalized approaches. Our standardized manufacturing creates reliable supply chains that work with existing healthcare infrastructure, eliminating the weeks-long delays of personalized therapies while providing powerful immune activation. The platform’s flexible, modular design adapts to emerging cancer targets, activates both B and T cells, and creates durable immune memory for sustained protection-all while enabling immediate treatment following diagnosis and streamlining regulatory pathways to make effective cancer care both powerful and accessible to patients worldwide.
IRZ-01 represents the cornerstone of our innovative OMV platform technology, engineered for industrial-scale production and cost-effective delivery. This breakthrough therapy is designed to provide immediate access to cutting-edge cancer treatment across multiple solid tumor indications including colorectal, endometrial, and gastric cancers.
Backed by Irazú Oncology’s executive leadership—bringing over a century of combined cancer drug development experience spanning more than 50 IND applications and two successful NDAs—IRZ-01 exemplifies our commitment to transforming cancer care. Our development process is further strengthened by our world-class advisory board comprising pioneering cancer researchers from prestigious institutions including Johns Hopkins, Harvard, and the University of Maryland.